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ochester, Minnesota; Cleveland, Ohio; Atlanta, Georgia; and Springfield, Illinois
s it approaches its fourth decade, percutaneous coronary intervention (PCI) is now the most widely used
evascularization strategy around the world and has been tested in multiple clinical scenarios against both
edical and surgical therapies. For each patient group and clinical scenario setting, the goals of therapy
ust be speciﬁcally deﬁned and clearly understood as an integral component of the process of selecting
he optimal strategy for the individual patient. In patients with chronic stable, often mild angina, the major
chievable goals of PCI are to affect symptoms, either by decreasing them or preventing them, reduce the
eed for subsequent procedures, and relieve ischemia. Achievement of these goals has been documented
n multiple randomized trials of PCI versus medical therapy. In these trials of patients with stable coronary
rtery disease (CAD), however, no reduction in death and myocardial infarction has been observed, and
hese limitations of PCI in this clinical setting need to be emphasized. Given the typically diffuse nature of
AD and the fact that PCI only treats a segment within a coronary artery, this is not surprising. Although
ptimal medical therapy forms the cornerstone of management for any patient with CAD, among stable
atients who do fail medical therapy, percutaneous coronary revascularization plays a well-documented
igniﬁcant role in improving symptoms and preventing the subsequent need for revascularization. The ap-
ropriate utilization rates of PCI in patients with chronic stable angina and preserved left ventricular func-
ion should lead to more cost-effective care of patients with stable CAD. (J Am Coll Cardiol Intv 2008;1:
4–43) © 2008 by the American College of Cardiology Foundationb
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pt has been 30 years since Gruentzig first used a
ercutaneous procedure to treat a patient with
oronary artery disease (CAD) (1,2). In that initial
pplication, a 37-year-old male with unstable an-
ina pectoris of recent onset underwent successful
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aper.e
anuscript received August 28, 2007; revised manuscript received
ctober 9, 2007, accepted October 26, 2007.alloon dilatation of a proximal left anterior de-
cending lesion. In 2000, at the age of 61 years,
hat patient had recurrent chest pain for the first
ime since the initial procedure. Angiography doc-
mented no significant stenosis at the site treated
n 1977.
Over the course of the past 3 decades, there have
een major advances in nonsurgical coronary re-
ascularization, and percutaneous coronary inter-
ention (PCI) has now become the most widely
sed revascularization procedure around the world.
lthough a substantial part of this growth has been
he consequence of the well-documented improve-
ent in outcomes of patients with the broad
pectrum of acute ischemic syndromes who un-
ergo PCI versus medical therapy (3–7), it is
rimarily the result of the application of PCI in
atients with chronic coronary disease who have
ither stable angina or a positive functional test
w
u
t
h
(
t
o
o
s
m
a
a
m
w
a
s
c
t
t
i
a
c
c
n
t
a
m
g
i
l
t
g
s
p
t
v
r
m
c
p
m
i
d
n
s
i
i
i
s
o
f
o
a
s
a
b
b
n
t
m
s
i
C
b
d
a
s
a
a
(
P
d
c
P
l
p
t
t
e
q
m
f
e
b
e
n
N
s
t
v
1
i
s
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 1 , N O . 1 , 2 0 0 8
F E B R U A R Y 2 0 0 8 : 3 4 – 4 3
Holmes, Jr. et al.
PCI for Chronic Stable Angina
35ith ischemia. On one hand, the burgeoning use of PCI is
nderstandable because of major technological advances in
he field, but it should be appreciated that, although PCI
as taken the place of coronary artery bypass grafting
CABG) as the most widely used mode of revascularization,
he major increase in the utilization of PCI has been because
f its use in patients formerly treated with medical therapy
nly. Patients and physicians frequently view coronary artery
tenosis as a mechanical problem to be “fixed” by mechanical
eans. Nonetheless, during the last few decades, there have
lso been profound improvements in approaches to primary
nd secondary prevention, and these sentinel advances in
edical therapy have generated new questions about
hether PCI may be overused as the initial therapeutic
pproach to patients with stable CAD and relatively mild
ymptoms. The consistent findings in generations of trials
omparing PCI and surgical revascularization with medical
herapy, together with recent advances in secondary preven-
ion, set the stage for a reappraisal of the critically important
ssue of optimal management of patients with chronic stable
ngina.
This discussion of therapeutic modalities needs to be
onsidered in relation to the overall goals of therapy in
hronic CAD. In this respect, the chronicity and progressive
ature of the disease processes are of paramount impor-
ance. Coronary disease is not cured by any currently
vailable therapies, but the natural history and prognosis
ay be modified. This is germane to all therapeutic strate-
ies, namely medical therapy, PCI, and surgical revascular-
zation. Potential targets of therapy include both short- and
ong-term goals that vary from prevention of clinical events
o the treatment of symptoms (Table 1).
The application of PCI in an attempt to achieve these
oals depends upon many factors, including the extent and
everity of the CAD, the baseline demographics of the
atient (including comorbidities), and the patient’s presen-
ation (e.g., an acute ischemic syndrome versus stable angina
ersus asymptomatic ischemia). The benefits of coronary
evascularization in patients with ST-segment elevation
yocardial infarction (STEMI) and non–STEMI acute
oronary syndromes (ACS) have been the subject of multi-
le trials, with the general consensus favoring an aggressive
echanical approach in patients with these syndromes and,
n particular, among those at higher risk (3–7). The present
iscussion will focus on patients with chronic stable angina,
ot on patients with ACS.
Irrespective of whether revascularization is performed
urgically or percutaneously, the landscape has changed
rrevocably in that aggressive secondary prevention is an
ntegral aspect of management. This has been an area of
ntense investigation, and there are robust evidence-based
ets of data that have been used to formulate guidelines for
ptimal care, which emphasize the benefits of aggressive risk
actor modification with diet, exercise, and treatment of ibesity, diabetes, hypertension, and hyperlipidemia, as well
s tobacco cessation. Specific adjunctive medical therapies
hould include administration of statins, aspirin, an
ngiotensin-converting enzyme (ACE) inhibitor in many
ut not all patients, and the judicious use of nitrates and
eta-blockers and calcium chan-
el blockers in symptomatic pa-
ients. Blood pressure control
ay require multiple drugs, and
ome lipid abnormalities require
nterventions beyond statins.
ontrol of hyperglycemia has
een proved critical in managing
iabetes. New antianginal agents
re under development, and one
uch drug, ranolazine, has been
pproved recently by the Food
nd Drug Administration
FDA) (8–10).
Consideration of the goals of
CI must take into account the
escription of what would be
onsidered to be “optimal
CI.” The technological revo-
ution, dominated by stent im-
lantation and advances in an-
ithrombotic and antiplatelet
herapies, is continuously
volving. As a direct conse-
uence, there has been a dra-
atic decrease in the need for urgent CABG surgery
ollowing PCI because the problem of acute or threat-
ned closure has been almost eliminated. In addition,
are-metal stents (BMS) have reduced, although not
liminated, clinical or angiographic restenosis and the
eed for repeat revascularization procedures (11–14).
onetheless, it should be emphasized that two decades of
tudies have not shown that conventional percutaneous
ransluminal coronary angioplasty (PTCA) improves sur-
ival in comparison with medical therapy (15–20) (Fig.
). Given the change from balloon dilatation to stent
mplantation, it is important to evaluate the effect of
tenting on the hard end points of death and myocardial
Table 1. Goals of Treatment
Relief or decrease of angina and ischemia
Prevention of progression of disease
Prevention of complications of disease including
Myocardial infarction
Worsening left ventricular function or development of congestive heart failure
Cardiovascular death
Sudden cardiac death or arrhythmias
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
ACS  acute coronary
syndromes
BMS  bare-metal stent(s)
CABG  coronary artery
bypass grafting
CAD  coronary artery
disease
DES  drug-eluting stent(s)
FDA  Food and Drug
Administration
LV  left ventricular
MI  myocardial infarction
PCI  percutaneous
coronary intervention
PTCA  percutaneous
transluminal coronary
angioplasty
STEMI  ST-segment
elevation myocardial
infarctionnfarction (MI). Two separate meta-analyses have been
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36ublished (Figs. 2 and 3). Brophy et al. (21) found no
ifference in death or MI between balloon angioplasty
nd stenting in 29 trials involving 9,918 patients. Al
uwaidi et al. (22) performed another meta-analysis of 23
rials that included 10,347 patients. This meta-analysis
emonstrated no significant difference between the tech-
iques in the frequency of death or MI. There was,
owever, a significant reduction in major adverse cardiac
vents. This was solely the result of a reduction in target
essel revascularization.
The subsequent development and widespread adoption of
rug-eluting stents (DES) further improved the outcome of
ercutaneous procedures by significantly reducing restenosis
ompared with BMS. In multiple series, the need for
ubsequent procedures with DES has been reduced to
ingle-digit frequency. Recently, the issues of stent throm-
osis have attracted considerable attention and generated
ontroversy (23–28). However, the data as a whole still
upport the following conclusions (Figs. 4 and 5):
. Drug-eluting stents significantly reduce restenosis com-
pared with BMS.
. Overall stent thrombosis rates are low and occur with
both BMS and DES.
. The timing of stent thrombosis appears to vary; stent
thrombosis with DES appears to occur somewhat later
than with BMS and may continue for a longer period of
time. Moreover, stent thrombosis is an unpredictable
event and is associated with severe consequences. Cessation
of clopidogrel is an important precipitating factor, but other
mechanisms must be operative in many patients.
. In carefully selected patient populations in the random-
ized trials leading to FDA approval, there was no
difference in death or MI during follow-up, irrespective
Figure 1. Results of a Meta-Analysis of Studies on the
Effect of PCI Versus Medical Therapy on Cardiac Death or MI
CI  conﬁdence interval; PCI  percutaneous coronary intervention;
pt  patients. Data from Katritsis et al. (15).of whether BMS or DES were placed. This, however, isnot a universal finding, and there appear to be differences
between trial and registry populations, particularly those
including patients with non–FDA-approved indications
for DES. For example, the DEScover registry enrolled
6,906 patients undergoing PCI at 140 medical centers
from January 2005 to June 2005. At 1 year, there was no
difference in the adjusted risk of death or MI between
DES and BMS. There were, however, no differences
in the rate of stent thrombosis. This is in contrast to
the Swedish Registry, which did not find a difference
in death and MI during 3 years of follow-up. How-
ever, there was a difference in the temporal profile,
with more adverse events in the first 6 months with
BMS and more events after 6 months with DES.
More data are needed particularly among higher-risk
patients who were excluded from the initial random-
ized trials.
. The optimal duration of dual antiplatelet therapy with
clopidogrel needs to be determined.
Optimal percutaneous approaches demand attention to
ntithrombotic and antiplatelet therapies (both periproce-
ural and after discharge) and multiple technical issues
elated to the placement of the stent; these include the
ppropriate size and length, selection of equipment, implanta-
ion techniques, and an awareness of comorbidities and their
otential interactions with the procedure (e.g., renal failure,
iabetes, and severe left ventricular [LV] dysfunction).
Recent trials of PCI versus medical therapy (COURAGE
Clinical Outcomes Utilizing Revascularization and Ag-
ressive DruG Evaluation]) and the MASS (Medicine,
ngioplasty, or Surgery Study)-2 trial of PCI, CABG, and
edical therapy have generated considerable interest and
gain draw attention to the issue of the appropriate indica-
ions for coronary revascularization and particularly PCI in
atients with chronic stable angina. In many respects, the
ndings of these contemporary trials should not come as a
Figure 2. Meta-Analysis of Stents Versus Conventional PTCA
on Rate of Death or MI, Angiographic Restenosis, and Repeat PTCA
MI  myocardial infarction; PTCA  percutaneous transluminal coronary
angioplasty. Data from Brophy et al. (21).
s
m
r
i
t
m
o
c
t
a
h
m
a
t
m
q
a
d
t
a
f
d
r
w
t
a
C
t
t
v
P
a
t
o
i
r
s
C
s
s
s
s
a
t
s
d
c
t
a
m
w
o
p
b
f
n
i
P
p
r
r
d
c
m
w
a
c
r
d
w
t
s
T
A
m
m
C
a
m
r
b
c
i
o
n
a
1
o
1
g
t
E
t
a
e
e
h
e
f
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 1 , N O . 1 , 2 0 0 8
F E B R U A R Y 2 0 0 8 : 3 4 – 4 3
Holmes, Jr. et al.
PCI for Chronic Stable Angina
37urprise because these are entirely consistent with the
ajority of prior trials over a 20- to 30-year period. In this
espect, a review of the results of previous randomized trials
n patients with chronic stable angina may help in placing
he recent trials into perspective.
Early trials in the 1970s and 1980s of CABG versus
edical therapy compared CABG during the learning curve
f this procedure with medical therapy that would be
onsidered entirely inadequate by today’s standards. None-
heless, the evidence-based data from these trials suggested
survival benefit only for surgery patients at medium or
igher risk, including those with LV dysfunction and
ultivessel disease. In patients with preserved LV function
nd stable angina Canadian Cardiovascular Society Class 1
o 2, there was no mortality benefit with surgery over
edical therapy. Subsequent registry studies demonstrated
uite clearly the survival benefits of revascularization only
mong patients with severe symptoms and multivessel
isease irrespective of LV function (29).
The next series of trials compared PTCA with medical
herapy in patients with stable angina. A recent meta-
nalysis demonstrated a lack of benefit in death and MI
rom PCI (15,18,19,30) (Fig. 1). Nonetheless, these studies
id convincingly identify greater relief of symptoms with
evascularization. More recent studies that included patients
ith stents were TIME (Trial of Invasive versus Medical
herapy in Elderly patients) in elderly patients with severe
ngina randomized to revascularization with either PCI or
ABG versus intensive medical therapy (31); the MASS-2
rial, which had three arms (CABG, PCI, or medical
herapy) (32); and the AVERT (Atorvastatin VErsus Re-
ascularization Treatments) trial of medical therapy versus
CI (19). In the AVERT trial, lipid lowering was less
ggressively performed in the interventional arm. None of
he trials demonstrated an advantage of revascularization
ver medical therapy in regard to death and MI. However,
n many trials, up to 50% of patients “crossed over” to
evascularization with PCI or CABG due to persistent
ymptoms that were refractory to antianginal drug therapy.
An important early trial was the ACIP (Asymptomatic
ardiac Ischemia Pilot) study of 558 patients with clinically
table, angiographically documented CAD who were judged
uitable for revascularization after being diagnosed with
ilent ischemia on 48-h Holter monitoring (33). Three
trategies were tested: 1) angina-guided medical therapy; 2)
ngina plus ischemia-guided therapy; and 3) revasculariza-
ion using either surgery or PTCA. In contrast to the
tudies above, total mortality, the combined end point of
eath or MI, and the end point of death, MI, or recurrent
ardiac hospitalization were significantly decreased in pa-
ients undergoing revascularization. This was a pilot study
nd emphasizes the importance of designing and imple-
enting larger adequately powered trials. Similar results
ere found in the SWISSI II (Swiss Interventional Study wn Silent Ischemia Type II) trial, a small trial of 201
atients with a prior MI and silent ischemia, which found a
enefit for PCI in regard to recurrent events over a 10-year
ollow-up period (34). Thus, it may be that, among the large
umber of patients with stable CAD, those with silent
schemia may be a high-risk group that can benefit from
CI.
In summary, the evidence-based message concerning
atients with chronic stable angina is clear and consistent: 1)
evascularization is associated with greater symptomatic
elief but there are no differences in the “hard” end points of
eath and MI; and 2) in patients on medical therapy,
rossover to revascularization is frequent. Therefore, in
any patients, a trial of medical therapy is very appropriate,
ith the understanding that if symptoms and quality of life
re not improved, the option of revascularization may be
hosen, and the price to be paid is not that of an increased
ate of death or MI. These data set the stage for a critical
iscussion of the most recent trial (COURAGE) (35),
hich has generated considerable emotion and some con-
roversy. The question to be addressed is whether the results
hould have come as a surprise.
he COURAGE Trial
s has been true with almost all randomized trials of
edical therapy versus a revascularization strategy, many
ore patients were screened than randomized. In the
OURAGE trial, 35,539 patients were initially screened,
nd 3,071 met eligibility criteria; of these 3,071 patients
eeting eligibility criteria, 2,287 were enrolled. It must be
emembered that all randomized trials are subject to “entry
ias.” This precept stands in contrast to registries, which are
haracterized by “selection bias.” The underlying hypothesis
n the COURAGE trial was that a strategy of PCI with
ptimal medical therapy would reduce the risk of death and
onfatal reinfarction compared with optimal medical ther-
py alone. The 3-year event rates were projected to occur in
6.4% of the PCI plus medical therapy group versus 21.0%
f the medical therapy group. The actual event rates were
9% in the PCI group and 18.5% in the medical therapy
roup.
Crucial to the understanding of this trial is an apprecia-
ion of the baseline characteristics of the patients enrolled.
ven though not all patients enrolled were at very low risk,
he trial was aimed at patients with stable disease and not
cute ischemic syndromes. Baseline characteristics of the
nrolled patients included: 1) 42% to 43% of patients had
ither no angina or only class 1 angina; 2) 30% of patients
ad single-vessel disease, and approximately 35% had dis-
ase involving the left anterior descending; 3) the ejection
raction was approximately 61% in both groups; and 4) DES
ere not routinely available.
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38In a patient such as was recruited for this trial, it is
nlikely that any revascularization strategy would improve
he rate of death and MI. With an 8% mortality rate at 5
ears and only 27% of those deaths being due to cardiac
auses, it would also be unlikely to show or expect a
ortality difference. Moreover, the rate of death, MI, and
troke is approximately 20% and very unlikely to demon-
Figure 3. Evaluation of the Effects of Routine Stenting Versus Conventiona
(A) Effects on death; (B) effects on reinfarction. AS  Angioplasty or Stent; BE
BOSS  Balloon Optimization versus Stent Study; CADILLAC  Controlled Abc
 Doppler Endpoint Stenting International Investigation; EPISTENT  Evaluatio
Stenting in Acute Coronary Occlusions; FROST  French Optimal Stenting Tria
coronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries; M
Coronary Balloon Angioplasty With Provisional Stenting Versus Primary Stent; O
With Routine Stent Strategy; OR  odds ratio; PASTA Primary Angioplasty Ve
Angioplasty after Recanalization of Chronic Coronary Occlusions; SISA  Stent
Total Occlusion; Stent-PAMI  Stent Primary Angioplasty in MI; STENTUIM  Im
with Conventional Balloon Angioplasty in Acute Myocardial Infarction; TOSCA
from Brophy et al. (22).trate a difference because neither noncardiac mortality nor tates of stroke would be expected to be reduced by PCI.
onsequently, the only modifiable hard end point would
ikely be MI and probably Q-wave MI because biomarker
levation occurs frequently after stenting. As previously
iscussed, only in patients at higher risk does revasculariza-
ion with PCI or CABG result in a reduction in death and
I. Even with the advent of DES, multiple randomized
A on Death and Reinfarction
NT  Belgian Netherlands Stent Study; BESMART  Bestent in Small Arteries;
and Device Investigation to Lower Late Angioplasty Complications; DESTINI
latelet IIb/IIIa Inhibitor for Stenting; FRESCO  Florence Randomized Elective
MI  Gianturco-Roubin in Acute Myocardial Infarction; ISAR-SMART  Intra-
Mayo-Japan Investigation for Chronic Total Occlusion; OCBAS  Optimal
 Optimum Percutaneous Transluminal Coronary Angioplasty Compared
tent Implantation in Acute Myocardial Infarction; SARECCO  Stent or
Small Arteries; SPACTO  Stent versus Percutaneous Angioplasty in Chronic
iate Coronary Angioplasty with Elective Wiktor Stent Implantation Compared
al Occlusion Study of Canada; other abbreviations as in Figure 2. Reprintedl PTC
NESTE
iximab
n of P
l; GRA
AJIC 
PUS
rsus S
ing in
med
 Totrials and registry studies have not documented a reduction
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39n the hard end points of death or infarction compared with
MS (23–25).
Given the inability of PCI to dramatically decrease death
nd MI in this patient population with stable symptoms,
elief of symptoms and prevention of the need for clinically
riven subsequent procedures remain more important from
patient standpoint. In the COURAGE trial, angina relief
as better and quicker in the PCI group. Subsequent
evascularization in the medical group was performed for
angina that was unresponsive to maximal medical therapy
r when there was objective evidence of worsening ischemia
n non-invasive testing.” Any subsequent revascularization
n this trial was therefore clinically driven and not related to
protocol requirement. PCI showed a significant advantage
ver medical therapy, with a subsequent revascularization
ate of 21.1% versus 32.6% in the optimal medical therapy
roup (hazard ratio 0.60, 95% CI 0.51 to 0.71, p  0.001).
ased on the documented reduction of restenosis with DES
Figure 3. Continued.ompared with BMS, it is reasonable to speculate that the cevascularization rates in the PCI group of the COURAGE
rial would have been likely significantly less had DES
een used. What was surprising and gratifying in the
OURAGE trial, however, was the high rate of angina
elief among medically treated patients. This may be the
esult of superb adherence to protocol-driven medical ther-
py. In the optimal medical therapy group, at 3 years, 75%
f patients were on an ACE inhibitor or angiotensin
eceptor blocker, 92% were on a statin, 86% were on a
eta-blocker, and 50% were on a calcium channel blocker.
imilar adherence to medical therapy was also present in the
CI group. This degree of adherence to evidence-based
herapy is infrequent in registry series (36).
Accordingly, we could conclude that in the group of
atients with stable angina and generally well-preserved
entricular function (ejection fraction approximately 61%),
he application of PCI in addition to optimal medical
herapy results in improvement of symptoms and a signifi-
ant decrease in the need for subsequent revascularization in
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40any patients. There are several explanations for the lack of
enefit of PCI in the COURAGE trial and other trials in
educing death or MI:
. Cardiac mortality rates in patients with stable angina in
the current era are low.
. It is possible that drug therapy and secondary prevention
improve endothelial function and stability over the long
term.
. The potential benefits of PCI of the culprit lesion or
lesions are diluted by the effects of disease progression in
other vessels or the failure to provide complete revascu-
larization initially.
Figure 4. Analysis of Randomized Trials of Sirolimus Versus BMS on Death
BMS  bare-metal stent; MI  myocardial infarction; TLR  target lesion revas
Figure 5. Analysis of Randomized Trials of Paclitaxel Versus BMS on DeathAbbreviations as in Figure 4. Reprinted from Stone et al. (23).. In patients with severe stenoses treated medically, col-
lateralization may play a role in alleviating symptoms,
although collaterals are generally an indication of severe
ischemia.
. Acute coronary syndromes secondary to ruptured plaques
occurs frequently at sites separate from areas of severe
stenosis, regardless of initial PCI. This observation is
also true for patients receiving optimal medical therapy
alone.
otential for overuse of PCI. Given that PCI in patients with
hronic stable angina is very effective in improving symp-
oms but has not been shown to decrease death or MI, why
nd TLR
zation. Reprinted from Stone et al. (23).
and TLR, MI, a, MI,
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41as there been such controversy about the potential for
veruse? Data from both Europe and the U.S. demonstrate
arked regional variations in the rates of PCI use, suggest-
ng that factors other than “evidence-based” medicine are
laying a role. For example, in a recent study of 11 states in
he U.S., variations in procedures performed per capita were
.83-fold for PCI and 1.54-fold for CABG. Variations in
he rate of cardiac catheterization accounted for 68% of the
ariability in rates of revascularization, and major indepen-
ent determinants of catheterization rates were the number
f cardiac surgeons and interventional cardiologists in a
articular state (37). Thus, it seems that this complex issue
f potential overuse of PCI has multiple components,
ncluding overuse of angiography, noninvasive coronary
ngiography, fear of litigation, financial incentives for pro-
iders, and self-referrals.
The variability in the rates of coronary angiography in
orth America and Europe is also quite striking. A single
nified explanation to account for this is not readily avail-
ble (38–40). Reasons may include access to catheterization
aboratories and availability of cardiologists, patient expec-
ations, the preference of the primary caregiver, the extent
nd application of specific screening approaches, and im-
lementation of evidence-based guidelines.
Patient desire for a “quick fix,” defensive medicine, and
 lack of understanding of therapeutic choices are addi-
ional confounders. This issue may become more prob-
ematic with the increased application of noninvasive
omputed tomography-based coronary angiography that
ay identify lesions in patients who are asymptomatic.
hen lesions have been identified with noninvasive coro-
ary angiography and patient reassurance becomes more
ifficult, this can be the catalyst for a cascade of events
ncluding coronary angiography and intervention.
Prior to invasive coronary angiography, there is often a
iscussion with the patient regarding the course of therapy
n the event that a significant lesion or lesions are found.
he scene is often set for percutaneous treatment if the
esion is deemed suitable. From the patient’s standpoint,
his makes intuitive sense to combine the diagnostic angio-
ram and the intervention in a single setting. This “conve-
ient” approach to treat what is there has become ingrained
nd is part of both patients’ and physicians’ expectations.
onetheless, the consequence may be the lost opportunity
o discuss all the therapeutic options in a less urgent setting
nd with all the information at hand.
To further complicate matters, payers in some regions
ave insisted that only interventionalists perform diagnostic
atheterizations so that any lesion found may be stented at
he time of the diagnostic procedure. The complex but real
ssues of financial incentives and self-referral cannot be
gnored and are an integral part of this discussion. Self-
eferral eliminates some of the checks and balances that are
 healthy aspect of the decision to choose among manyffective options. Likewise, cost-effectiveness is an impor-
ant component. Claude et al. (41) analyzed this in elderly
atients with chronic angina. Patients undergoing an inva-
ive approach had higher 30-day costs but lower 2- to
2-month hospital and interventional costs than medically
reated patients. Medical patients had higher practitioner
harges.
onclusions
hat then can be said about the role of PCI in the current
ra? First and foremost, in patients with stable angina and in
eneral well-preserved LV function who are beginning or
re already on optimal medical therapy, application of PCI
oes not reduce the frequency of subsequent MI or cardiac
eath; it does, however, significantly reduce angina. PCI
lso reduces the need for subsequent additional procedures.
n appropriate approach is to initiate a trial of medical
herapy and aggressive risk factor reduction in patients with
ild stable angina who are amenable to this strategy,
ushioned by the security of knowing that a subsequent
rossover to PCI does not come at the price of increased
eath or MI. A crucial aspect of this discussion is a
horough understanding of the patient’s realistic expecta-
ions: the impact of angina upon lifestyle and the ability to
olerate medical therapy. Moreover, comprehensive second-
ry prevention remains the bedrock of both strategies.
Second, DES have been found to be associated with
ignificant reduction in restenosis and thereby may further
mprove anginal relief in both stable and unstable patients.
he issue of stent thrombosis continues to require further
tudy, as does the most appropriate duration of dual
ntiplatelet therapy.
Finally, the appropriate rates of use are a major concern
ith important socioeconomic implications. What is
eeded is to establish whether use is appropriate, and, if not,
hy not? It is up to the cardiovascular community to ensure
hat evidence-based medicine dominates clinical practice.
he Clinical Competence Statement on Interventional
ardiology of the American College of Cardiology, Amer-
can Heart Association, and Society for Cardiac Angiogra-
hy and Interventions advances suggestions for maintaining
uality and ensuring appropriate selection of these proce-
ures (42). The credibility of what we as cardiologists do
nd how we implement coronary revascularization places
he onus of responsibility on us.
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ochester, Minnesota 55905. E-mail: holmes.david@mayo.edu.
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